Clinical trial
Monoclonal Antibody F19 in Treating Patients With Advanced or Metastatic Cancer
NCT00004042 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00004042 |
|---|---|
| Title | Monoclonal Antibody F19 in Treating Patients With Advanced or Metastatic Cancer |
| Official title | A Phase I Dose-Escalation Study of BIBH-1 in Patients With Advanced or Metastatic Fibroblast Activation Protein-Positive Cancer |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Biological, Radiation |
| Interventions | monoclonal antibody F19, iodine I 131 monoclonal antibody F19 |
| Enrollment | 24 |
| Start date | Nov 1, 1998 |
| Primary completion | Jul 1, 2001 |
| Completion | Dec 1, 2009 |
| First posted | Aug 20, 2004 |
| Last update posted | Jul 18, 2013 |
| Countries | Australia, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: